Immunobiochemical markers of inflammation in development of age-associated dementia
Suggested citation:
Androsova LV, Mikhaylova NM, Zozulya SA, et al. [Immunobiochemical markers of inflammation in development of age-associated dementia]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2017;(4):61-66. Russian
The aim of the study was to reveal the changes in a number of indicators of the inflammatory system: the activity of leukocyte elastase and the α1-proteinase inhibitor, the concentration of C-reactive protein and interleukin-6 in the blood plasma of patients with age-dependent cognitive disorders, Their relationship with clinical indicators in individuals with Alzheimer's disease and other forms of dementia to search for new early diagnostic markers for the progression of cognitive deficits. 187 patients were examined. The diagnosis of dementia was established in accordance with the criteria ICD-10 and NINCDS-ADRDA. The activity of leukocyte elastase and α1-proteinase inhibitor was determined by spectrophotometric method, the concentration of interleukin-6 and C-reactive protein by the enzyme immunoassay. The obtained data suppose the different level of inflammation markers in studied forms of dementia, and the difference in their dynamics during the course of the disease development. It can be used as an additional diagnostic and prognostic criterion during clinical examination of patients.
1. Gavrilova SI, Kolykhalov IV, Fedorova IaB, et al. [Prognosis of cognitive deficit progression in aged patients with mild cognitive impairment under prolonged therapy (a three year observation)]. [Zh Nevrol Psikhiatr Im S S Korsakova]. 2013;113(3):45-53. (In Russian). 2. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain. J Neuroimmunol. 2000;103(1):97-102. 3. Schram MT, Euser SM, de Craen AJ, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007;55(5):708-16. doi:10.1111/j.1532-5415.2007.01159.x 4. Holmes C, Butchart J. Systemic inflammation and Alzheimer's disease. Biochem SocTrans. 2011;39(4):898-901. doi: 10.1042/BST0390898. 5. Varma VR, Varma S, An Y, Hohman TJ, et al. Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. Mol Psychiatry. 2017;22(1):13-23. doi:10.1038/mp.2016.206. 6. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-44. 7. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250-60. 8. Zekry D, Hauw JJ, Gold G. Mixed Dementia: Epidemiology, Diagnosis, and Treatment. JAGS.2002;50(8):1431-8. 9. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br. J. Psychiatr. 1982;140(3):566-572. 10. Folstein MF, Folstein SF, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 1975;(12):189-98. 11. Dotsenko VL, Neshkova EA, Yarovaya GA. [Detection of leukocyte elastase from complex with plasma α1-protease inhibitor by it enzymatic activity with a synthetic substrate]. Voprosy meditsinskoy khimii [Vopr. Med. Khimii]. 1994;40(3):20-5. (In Russian). 12. Nartikova VF, Paskhina TS. [A unified method for assay of alpha1-antitrypsin and alpha-2-macroglobulin activity in human serum (plasma)]. Voprosy meditsinskoy khimii [Vopr. Med. Khimii]. 1979;25(4):494-9. (In Russian). 13. Lebedev KA, Ponyakina ID. [Immunology of the image recognition receptors (integral immunology)]. M.: LIBROKOM, 2009. 256 p. (In Russian). 14. Ravari A, Mirzaei T, Kennedy D, et al. Chronoinflammaging in Alzheimer: A systematic review on the roles of toll like receptor 2. Life Sci. 2017;171:16-20. doi: 10.1016/j.lfs.2017.01.003 15. Androsova LV, Simashkova NV, Shushpanova OV, et al. [The possibility of using immunological parameters for the evaluation of the clinical state of patients with childhood-onset schizophrenia]. [Zh Nevrol Psikhiatr Im S S Korsakova]. 2016;116(2):85-9. doi: 10.17116 / jnevro20161162185-89 (In Russian). 16. Klyushnik TP, Androsova LV, Simashkova NV, et al. [Clinico-laboratory diagnostics of autism spectrum disorders in Children]. Laboratornaya sluzhba [J Laboratory Service]. 2016;5(2):22-7. Doi: 10.17116 / labs20165222-27 (In Russian). 17. Zozulya SA, Oleichik IV, Androsova LV, et al. [Monitoring of the course of endogenous psychoses by immunological parameters]. Psikhicheskoye zdorov'ye [Mental Health]. 2017;(1):11-8. (In Russian). 18. Davydova TV, Fomina VG, Voskresenskaya NI, et al. [Phagocytic activity and state of bactericidal systems in polymorphonuclear leukocytes from patients with Alzheimer's disease]. [Bull Exp Biol Med]. 2003;136(10):403-5. (In Russian). 19. Le Page A, Lamoureux J, Bourgade K, et al. Immune signatures of Alzheimer’s disease: profiles of neutrophils. (HUM 1P.30 1). The Journal of Immunology. 2015;194 (Suppl. 1):52.
DOI: http://dx.doi.org/10.24411/1560-957X-2017-1%25x
Article Metrics
Metrics powered by PLOS ALM